-
Relapsed and refractory AML is a very difficult clinical problem, and there is currently no unified and efficient treatment plan.
Relapsed and refractory acute myeloid leukemia (AML) presents one of the most formidable challenges in oncology, lacking a unified and efficient treatment strategy. Dr. Johannes Schetelig, Head of the Cell Therapy Unit at the Technical University of Dresden and Chair of the Clinical Trials Unit within the DKMS, offers invaluable insights into the complexities and…
-
2024 Edition of CSCO Kidney Cancer Guidelines Surgical Updates | 2024 CSCO Guidelines Conference
Hosted jointly by the Chinese Society of Clinical Oncology (CSCO) and the Beijing Hisco Clinical Oncology Research Foundation, the 2024 CSCO Guidelines Conference was held in Jinan on April 26-27. It is understood that updates to the CSCO guidelines for kidney cancer treatment are currently under discussion. “Oncology Frontier” interviewed Professor Pei Dong from the…
-
Expert Perspective | Professor Dong Ji: Prognostic Studies on Drug-Induced Liver Injury
Drug-induced liver injury (DILI) is liver damage caused by prescription or over-the-counter chemical medicines, biological products, traditional Chinese medicines, herbal and natural medicines, health products, dietary supplements, or their metabolites, additives, contaminants, and impurities. It is one of the most concerning drug-related diseases globally. At the inaugural 2024 Jinling Liver Disease Conference, Professor Dong Ji…
-
Professor Qing Cao’s Team: FA-ME Improves Diagnostic Efficacy for Children with Meningitis/Encephalitis | ESCMID Global 2024
Despite ongoing developments in antimicrobial drugs and vaccines, the diagnosis of bacterial meningitis and viral encephalitis remains challenging due to their varied clinical presentations and is closely associated with high mortality rates. Traditional diagnostic methods have limitations, such as low positivity rates and lengthy processing times for cerebrospinal fluid (CSF) cultures, making early clinical diagnosis…
-
2023 COMB丨Professor Peng Yuan: Precision Diagnosis and Treatment Strategies for Young Breast Cancer
The 6th Precision Oncology Summit and the 9th Individualized Breast Cancer Treatment Conference (2023 COMB) were held from December 23 to 26, 2023, in a hybrid online and offline format. Professor Yuan Peng from the Cancer Hospital of the Chinese Academy of Medical Sciences delivered a lecture on “Precision Diagnosis and Treatment Strategies for Young…
-
2023 COMB Conference | Professor Qiao Li : Current and Future Perspectives on Neoadjuvant Research for TNBC
Triple-negative breast cancer (TNBC) is a highly aggressive and heterogeneous subtype of breast cancer, accounting for 15% to 20% of all breast cancers. Compared to other subtypes, TNBC patients often experience rapid clinical progression, are diagnosed at a younger age, have faster distant recurrence, and more common visceral metastasis. Treatment for TNBC is usually limited…
-
Consensus on Targeted Prostate Biopsy at Panjiayuan by National Cancer Center
In recent years, the incidence and mortality rates of prostate cancer in China have been rapidly increasing. Early diagnosis and treatment are crucial, with prostate biopsy histopathology being the gold standard for diagnosis. However, differences in equipment and technical levels among medical institutions in China pose challenges for prostate biopsies, including issues with technique selection…
-
VLA-4 Agonists – Enhancing Hematopoietic Stem Cell Engraftment, Accelerating Immune Reconstitution, and Increasing Treatment Success Rates for Patient
Hematopoietic stem cell transplantation (HSCT) is an effective, and often the only, curative treatment for malignant hematological diseases such as leukemia. Key steps that impact the success of the transplantation include stem cell engraftment and the reconstitution of immune functions. From April 14 to 17, 2024, the 50th European Society for Blood and Marrow Transplantation…
Connecting Medical Expertise through Media